Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study

Anti-cancer Drugs
Evangelos BriasoulisGeorge Fountzilas

Abstract

This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. Patients with advanced cancer were eligible for this trial. Dose-limiting toxicity (DLT) was considered to be any grade greater than or equal to 3 (G> or =3) nonhematological toxicity except nausea/vomiting, G4 hematological toxicity of more than 4 days without recombinant human granulocyte colony-stimulating factor support, concurrent diarrhea G> or =2 and neutropenia G> or =3, and a treatment delay for more than 14 days because of toxicity. Patients were given carboplatin area under the curve (AUC) 5 mg*min/ml on day 1 combined with irinotecan and paclitaxel on days 1 and 8, every 3 weeks. The starting dose of both irinotecan and paclitaxel was 50 mg/m and a toxicity-guided escalation/de-escalation was planned by 10 mg/m steps. Sixteen patients were enrolled. DLTs occurred in three of the four patients treated at the starting dose level, which defined that dose as the maximum tolerated dose. Accrual continued with irinotecan and paclitaxel doses, which were de-escalated by one step. At this dose level, two of the 12 patients developed DLT, which defined that dose as the RSD. ...Continue Reading

References

Jun 1, 1995·British Journal of Cancer·M E GoreM Nicolson
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L B SaltzD Kelsen
Aug 12, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BriasoulisN Pavlidis
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E BriasoulisN Pavlidis
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A SocinskiR B Natale
Jun 5, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D PectasidesA Athanassiou
Sep 3, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T KasaiS Kohno
Jun 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Katsuyuki HottaMitsune Tanimoto
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BriasoulisN Pavlidis
May 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G BocciM Del Tacca
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Gyo AsaiMasahiro Fukuoka
Sep 1, 2007·American Journal of Clinical Oncology·Fumihiro OshitaKazumasa Noda
Apr 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ana M Gonzalez-Angulo, Gabriel N Hortobagyi
Nov 1, 2008·Cancer Research·Vincent T DeVita, Edward Chu
Oct 8, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evangelos BriasoulisNicholas Pavlidis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.